Novartis Ag

Biosynthema Inc.

Akzo N.v.

Eric Paul Krenning

Steven W Lamberts

Rainer Albert

Janos Pless

Marion DeJong

Marion De Jong

Petrus Martinus Van Hagen

Edgar Rolleman

Georg Hennemann

The invention relates to a combination of a solution of a gelatin derivative and at least one amino acid, if desired in the form of a pharmaceutically acceptable salt or carboxylic acid derivative, for inhibiting renal uptake of substances, that are potentially damaging for the kidneys, in a living being.

Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take

The invention relates to compounds having a binding affinity for both the &#x3b1;v&#x3b2;3 receptor and a (neuro)peptide receptor, in particular the somatostatin receptor, which compound comprises a first peptide part comprising at least once the amino acid sequence Arg-Gly-Asp, and a second peptide part coupled thereto, optionally via a linker, which second peptide part is a (neuro)peptide.

RGD (Arg-Gly-Asp) coupled to (neuro)peptides

The invention relates to a new pharmaceutical use of somatostatin peptides comprising on the terminal amino group a polyamino polycarboxylic group, in free form or in a pharmaceutically acceptable salt form, particularly in the manufacture of a medicament for treating disorders with an aetiology comprising or associated with excess of GH-secretion.

Therapeutic use of somatostatin peptides

Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.

Chelated somatostatin peptides and complexes thereof, pharmaceutical

Use of certain complexed somatostatin peptides for the invivo imaging of

Disclosed are sustained release dosage forms of liothyronine, in combination with normal or sustained release of thyroxine in a molar ratio of about 1 to 50:1, especially 5 to 20:1, useful in thyroid hormone replacement therapy. Surprisingly, it is found that by incorporating liothyronine and optionally thyroxine into a prolonged action dosage form in the described ratios, that the side effects associated with thyroid hormone replacement therapy are greatly reduced or eliminated. The preparation can be a dosage form containing salts of both thyroxine and liothyronine which release in a sustained manner. The preparations will typically contain 5 to 25 .mu.g of liothryronine. Also disclosed are processes of manufacturing the pharmaceutical preparations. The compositions are useful in treating disease states such as hypothyroidism, hyperthyroidism (in combination with thyrostatic drugs), so-called 'TSH' suppressive therapy, and depression.

Growing community of inventors

Rotterdam, Netherlands

Eric Paul Krenning